Fate Therapeutics

$89.72
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$3.45 (+4.00%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell FATE and other stocks, options, and ETFs commission-free!

About FATE

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products include immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA. The listed name for FATE is Fate Therapeutics, Inc. Common Stock.

CEO
J. Scott Wolchko
Employees
178
Headquarters
San Diego, California
Founded
2007
Market Cap
9.17B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.06M
High Today
$93.29
Low Today
$84.09
Open Price
$88.45
Volume
1.20M
52 Week High
$121.16
52 Week Low
$16.75

FATE Earnings

-$0.68
-$0.54
-$0.41
-$0.27
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.39 per share
Actual
-$0.61 per share
Replay Earnings Call

You May Also Like

VINO
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure